| abstract |
The present disclosure relates to a method for preventing end-stage renal disease using an angiotensin II antagonist in a patient having renal dysfunction. Candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[(2'-tetrazol-5-yl) biphenyl-4-yl) methyl] imidazolecarboxylic acid and 3- (2 '-(tetrazol-5-yl) -1,1'-biphen-4-yl) methyl-5,7-dimethyl-2-ethyl-3H-imidazo [4,5-b] pyridine or them Angiotensin II antagonists such as the pharmaceutically acceptable salts of are useful. |